Introduction
Nitric oxide (NO) is a cell-signaling molecule produced by NO synthases (NOS) from l-arginine. At present, three different isoforms of NOS are known, endothelial (e), neural (n), and inducible (i) NOS. 1 NO is an important modulator of the immune system, vascular tone and angiogenesis. [2] [3] [4] [5] [6] [7] [8] There is growing evidence to suggest that eNOS-mediated NO release in endothelial cells is regulated by vascular endothelial growth factor (VEGF). [9] [10] [11] [12] [13] [14] [15] [16] Moreover, the role of VEGF and its receptors in angiogenesis is obvious, and has been recently reviewed by Veikkola and coworkers. 17 Hematopoietic tissue is a target of NO. More specifically, NO may act as a mediator in cytokine-induced suppression of hematopoiesis. 18 Furthermore, NO has been shown to inhibit CD34-positive progenitor cell proliferation. 19 NO also influences leukemia cell growth and differentiation: NO-releasing compounds have anti-proliferative and apoptotic effects on leukemia cells, 20, 21 while exogenous or TNF-␣-induced NO induces monocytic differentiation in these cells. 22, 23 On the other hand, an antiapoptotic effect of NO on lymphatic cells has been documented, [24] [25] [26] which mechanism is, at least in some cases, due to inhibition of the Fas pathway. 24, 25 Furthermore, the inhibitors of NOS have been found to induce apoptosis in leukemia cells. 26, 27 Quite recently, Kolb reviewed the role of NO in human leukemia and concluded that apoptosis induced by NO by chemical donors are related with myelomonocytic lineage cells while anti-apoptotic effects of NO are associated with the delivery of endogenous NO by NO synthases and are observed mostly in lymphatic cells. 28 Interestingly, hematopoietic and endothelial cells have a common progenitor cell, hemangioblast. 29 Furthermore, studies carried out with knockout mice have shown that if Flk-1/ KDR, the VEGF receptor-2 (VEGFR2) through which VEGF signaling takes place, is omitted during an early stage of embryogenesis, the development of vasculogenesis and hematopoiesis is either lacking 30 or highly defective. 31, 32 On the other hand, very primitive pluripotent hematopoietic stem/progenitor cells express Flk-1/KDR, which effect, however, disappears when the cells are committed to differentiate. 33 Thus, it can be speculated that Flk-1/KDR might have a special role in keeping hematopoietic cells at the 'stem cell level'.
Acute myeloid leukemia (AML) is a clonal disease, which may originate at the level of the pluripotent stem cell. 34 However, the leukemia cell population is very heterogeneous, and only a minority of the cells are true clonogenic stem cells, which retain their self-renewal capacity in long-term culture. 34 Quite recently, it has been observed that VEGF and its receptors, Flt-1 and Flk-1/KDR, are also expressed in malignant myeloid hematopoietic cells. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Furthermore, an association of AML with increased bone marrow microvessel density, as observed by Padro et al, 45 supports an important role of angiogenetic factors in leukemia cell growth.
Our aim here was to analyze the hypothesis, of whether the VEGF signaling pathway modulates NOS in AML, resulting in the regulation of leukemia cell growth, since these two signaling pathways co-operate so well in the case of endothelial cells.
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Materials and methods
AML cell lines and cell culture
The human myeloid cell lines, U937 and HL-60, were purchased from American Type Culture Collection (Bethesda, MD, USA). The human AML cell line OCI/AML-2, established at the Ontario Cancer Institute, Toronto, Canada, 46 was a gift of Dr EA McCulloch. The cell lines were grown in a suspen-Leukemia sion with a density of 5 × 10 5 cells/ml in ␣-minimal essential medium (␣-MEM), and in the case of U937, in RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) in an atmosphere of 95% air and 5% CO 2 at 37°C. The medium was normally changed 2-3 times per week. Fresh medium was added 24 h before each experiment to ensure exponential growth of the cells.
Cells for the Akt kinase assay were grown in ␣-MEM with 0.5% FBS for 48 h and thereafter in ␣-MEM without FBS for 2-4 h just before addition of agents under investigation.
Bone marrow samples
Fourteen histopathologically typical cases of AML were randomly retrieved from the files of the Department of Pathology, Oulu University Hospital. Apart from light-microscopic evaluations of bone marrow (BM) biopsies, the AML diagnoses were based on BM aspirates and special stainings according to the French-American-British (FAB) classification criteria 47 and on the immunophenotyping of the leukemia cells. Two BM samples of normal histology were used as controls. The BM samples had been taken from the patients after informed consent during routine diagnostic and treatment evaluations between January 1992 and December 1998 in the Leukemia Treatment Unit at the Department of Internal Medicine, Oulu University Hospital. FAB subtypes of the AML cases are shown in Table 1 .
Cell proliferation assay for clonogenic cells
When the effect of the agent on clonogenic cell growth was investigated, the exposed OCI/AML-2 cells were washed twice with 1× phosphate-buffered saline (PBS) and plated into methylcellulose (mc). Roughly, 1 × 10 3 viable cells/well were cultured in a volume of 0.1 ml of basic growth medium (10% FBS in ␣-MEM) and 0.9% mc in 96-well microtitre plates Table 1 Immunohistochemistry of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) and receptor-2 (Flk-1/KDR) in bone marrow biopsies of de novo acute myeloid leukemia (AML) is a specific PI3-K inhibitor and was used at a concentration of 50 mol/l. N G -Nitro-l-arginine Methyl Ester (L-NAME; Calbiochem) at a concentration of 10 mmol/l was used for the inhibition of NOS. Sodium nitroprusside (SNP; Sigma, St Louis, MO, USA) of 1 mm was used as a NO donor.
The concentrations used were based on titrations on the OCI/AML-2 cell line. Reagents and cell cultures were protected from light with aluminium foil, when appropriate. Cell density was adjusted to 5 × 10 5 /ml at the beginning of the exposure, and exposure time was principally 48 h, after which the cells were counted and prepared for further analyses as described elsewhere.
Cell viability assays Trypan blue exclusion test:
Cell viability was mostly determined by the trypan blue exclusion test.
XTT cytotoxicity assay:
The microculture tetrazolium dye (XTT) colorimetric assay (Boehringer Mannheim, Mannheim, Germany) was used to quantify cytotoxity according to the manufacturer's instruction.
Annexin V assay:
Fluorescein iso-thiocyanate (FITC)-conjugated annexin V (Boehringer Mannheim, Mannheim, Germany) with propidium iodide (PI) was used in flow cytometry to detect apoptotic and necrotic cells. For the analyses, cells were harvested from the suspension cultures, washed twice with PBS and incubated in Annexin V-Fluos labeling solution (2% Annexin-V-Fluos and 1.0 g/ml propidium iodide in 10 mm Hepes/NaOH, pH 7.4; 140 mm NaCl; 5 mm CaCl 2 ) for 15 min at room temperature in the dark. After the incubation, the cells were washed twice with Hepes buffer and analysed by using a FACSort flow cytometer (Becton 
Analysis of protein expression
Immunohistochemistry:
Sections of 4 m thickness were deparaffinized in xylene and rehydrated in graded ethanol. Endogenous peroxidase was consumed by incubating the sections in 30% hydrogen peroxide in absolute methanol for 10 min. The sections were incubated with the primary antibodies at room temperature for 1 h, followed by the biotinylated secondary antibody and peroxidase-conjugated streptavidin included in the Histostain-PLUS kit (Zymed Laboratories, South San Francisco, CA, USA). The color was developed with aminoethyl carbazole substrate solution (Zymed Laboratories). The sections were counterstained with a light hematoxylin stain. The negative controls were made by substituting PBS at pH 7.2 and using the isotypes recommended by the manufacturer. Scar and granulation tissues from healing wounds were used as positive controls for Flt-1 and Flk-1/KDR. In addition, as an internal positive control we used blood vessels which showed positive staining in all the samples studied. The staining reaction was graded as negative or positive according to the presence of cytoplasmic staining in the cells.
The following primary antibodies were used: the monoclonal antibody for iNOS (dilution 1:60) was obtained from Transduction Laboratories (Lexington, KY, USA) and the polyclonal antibody for eNOS (dilution 1:50) from Santa Cruz Biotechnology (San Diego, CA, USA). The monoclonal antibodies for VEGF (dilution 1:250), Flt-1 (dilution 1:100), and Flk-1/KDR (dilution 1:250) were purchased from Santa Cruz Biotechnology.
Flow cytometry:
For the analyses, 1-2 × 10 6 viable cells were harvested from the suspension cultures and washed twice with PBS, whereafter they were treated with 70% cold ethanol for 15 min and washed twice with PBS. The permeabilized cells were incubated for 30 min at room temperature with one of the antibodies or a non-specific mouse isotype control. The antibody-treated cells were washed twice with PBS and incubated with FITC-conjugated rabbit anti-mouse F(ab) 2 fragments (Dakopatts, Glostrup, Denmark) for 30 min. After that, the cells were washed twice with PBS, and a total of 10 4 cells were analyzed by using a FACSort flow cytometer (Becton Dickinson). The following monoclonal antibodies were used in the flow cytometer analyses: Flk-1/KDR (also designated VEGFR2) from Santa Cruz Biotechnology, VEGF (Ab-3) from Oncogene Research Products, and eNOS from Transduction Laboratories.
Western blotting:
The cells were harvested and washed twice with ice-cold PBS. 2 × 10 6 cells were lysed in 100 l of Laemmli buffer. After 10 min on ice, the lysed cells were centrifuged at 750 g for 4 min and the supernatant was collected and stored at −80°C. Twenty-five l of cell lysate was applied to 12% SDS-PAGE (Bio-Rad Laboratories, Hercules, CA, USA) and transferred on to a Hybond nitrocellulose membrane (Amersham Life Science, Buckinghamshire, UK). After blocking for 60 min with 10% dried fat-free milk in Tris-buffered saline-Tween (TBS-T) (20 mm Tris-HCl pH 7.6, 137 mm NaCl, 0.1% Tween-20), the membranes were incubated for overnight at 4°C with the primary rabbit polyclonal antibody.
Leukemia
All the antibodies were diluted in TBS-T with 5% BSA at 1:1000. The primary antibodies used were Phospho-Akt kinase (Ser 473) and Akt kinase (Cell Signaling Technology). The specific protein-antibody complex was detected using a horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (Cell Signaling Technology), and an enhanced chemiluminescence (ECL) detection kit (Amersham). In addition, ␤-actin expression of the cells was detected with a monoclonal anti-actin antibody (1:10 000) using a HRP-conjugated anti-mouse secondary antibody (Amersham).
Protein quantification by ELISA:
eNOS was quantified using Quantikine, a human eNOS immunoassay from R&D Systems (Minneapolis, MN, USA) according to the manufacturer's instructions. The results are expressed as pg/ml of cell lysate, when 1.5 × 10 6 viable cells are lysed in 120 l of Cell Lysis Buffer.
VEGF was quantified from AML cell culture medium using the Human VEGF ELISA, a non-isotopic immunoassay from Oncogene Research Products, according to the manufacturer's instructions. 5 × 10 5 cells were cultured in 1 ml of culture medium. In the case of specific exposure the culture time was 48 h. It was extended for up to 4 days when the basal VEGF production of the cells was estimated. The results are expressed as ng/ml of medium.
Protein quantification in both immunoassays was done with a microculture plate reader (Victor) at 450/540 nm.
NOS activity
The NOS assay kit from Cayman Chemical Company (Ann Arbor, MI, USA) was used for the determination of nitric oxide synthase (NOS) activity. The NOS assay kit is based on the biochemical conversion of l-arginine to l-citrulline by NOS. 3 H-arginine is added to protein extracts. After incubation, the reactions are stopped with a buffer containing ethylenediaminetetra-acetic acid (EDTA), which chelates the calcium required by NOS and, consequently, inactivates the NOS. Equilibrated resin, which binds to the arginine, is added to the sample reactions and the reactions are then pipetted into spin cups. The citrulline, being ionically neutral at pH 5.5, flows through the cups completely. The NOS activity is then quantified by counting the radioactivity in the eluate.
Viable cells 4 × 10 6 (with or without exposure) were homogenized with the homogenization buffer applied by the manufacturer, after which the sample was centrifuged and the supernatant collected. The protein content of the lysate was determined by Bio Rad protein assay (Bio-Rad Laboratories). Fifty g of the protein lysate was taken for analysis. The assay was repeated three times according to the manufacturer's instructions. Radioactivity was determined using a Wallac scintillation spectrophotometer. The results are presented as percentages of the control (no exposure).
Results
Expression of NOS, VEGF and VEGF receptors by immunohistochemistry
Immunohistochemistry was used to study the BM samples obtained from patients with AML. Two normal BM samples were first studied, for comparison. In normal BM, eNOS expression was observed in immature myeloid cells, while more mature cells appeared negative. About 5-10% of the hematopoietic cells expressed eNOS, and the positive cells were located in clusters ( Figure 1A ). Positivity could occasionally be observed in megakaryocytes. Staining with VEGF was analogous, showing positivity in immature myeloid cells, while more mature cells and neutrophils were negative. About 5-10% of the hematopoietic cell population expressed VEGF. Megakaryocytes did not express VEGF. VEGF receptor-2, ie Flk-1/KDR, was much less intensively expressed than VEGF, and immunoreactivity was also observed in immature cells. Less than 5% of the hematopoietic cell population showed Flk-1/KDR positivity. Megakaryocytes were negative for Flk-1/KDR. In normal BM, iNOS expression was observed in the more mature differentiated cells of the myeloid lineage ( Figure 1B) . Cells of the erythroid series appeared negative. Occasional positivity was observed in megakaryocytes.
The percentage of positively stained blast cells in 14 AML samples is shown in Table 1 . All AML samples showed eNOS positivity ranging from 5 to 80% per case, while VEGF positivity was only observed in 9/14 samples, ranging from 5 to 10%. Furthermore, Flt-1 positivity was only observed in 8/14 samples, while Flk-1/KDR was shown in each of the 13 samples studied. In these samples, positivity ranged from 5 to 90%. Blast cells did not express iNOS. However, in more differentiated myeloid cells iNOS expression varied from 5 to 40%.
An example of the eNOS, iNOS,Flk-1/KDR and VEGF staining pattern in AML is shown in Figure 1C , D, E and F, respectively.
Expression of NOS, Flk-1/KDR and VEGF in AML cell lines by flow cytometry
Three AML cell lines, OCI/AML-2, HL-60 and U937, were studied by flow cytometry for the expression of NOS, Flk-1/KDR and VEGF. Expression of eNOS, Flk-1/KDR and VEGF was obvious in all the three cell lines, and representative histograms of the OCI/AML-2 cell line are shown in Figure 2 . Expression of iNOS was much less intensive in the HL-60 cell
Figure 2
Expression of eNOS, Flk-1/KDR and VEGF in the OCI/AML-2 cell line. Determination was done by flow cytometry using specific monoclonal antibodies and FITC-conjugated F(ab) 2 fragments in a two-step staining method. The left (white) histogram on each column represents an irrelevant isotype control and the right (black) histogram the corresponding specific antibody.
Leukemia line, negligible in the OCI/AML-2 cell line, and was not observed in the U937 cell line.
Quantification of VEGF in AML cells
Since we found by flow cytometry the AML cell lines to produce VEGF, we quantified its production using ELISA assay. We found that the VEGF concentration in the culture medium increased time dependently, correlating with the increase in cell number. In the case of OCI/AML-2 cells, the amount of VEGF was 92 ± 39 ng/ml after 1 day of culture, 313 ± 121 ng/ml after 2 days of culture, 1413 ± 689 ng/ml after 3 days of culture, and 4388 ± 2222 ng/ml after 4 days of culture (mean ± s.d., n = 3). VEGF production was also measured in two other AML cell lines, HL-60 and U937, the production after 3 days being 2350 ± 445 ng/ml and 1138 ± 48 ng/ml, respectively.
Quantification of eNOS in OCI/AML-2 cells
eNOS expression was studied in more detail in OCI/AML-2 cells. eNOS was quantified from cell lysate using ELISA-assay, and it was 184 ± 65 pg/ml of lysate (1.5 × 10 6 cells/120 l) (n = 6) in basic growth conditions.
Effect of the VEGF signaling pathway inhibitors on AML cell survival and clonogenic cell growth
The effect of inhibitors of the VEGF/Flk-1/KDR signaling pathway on clonogenic cell growth of the OCI/AML-2 cell line is shown in Figure 3 . Although we could not find any effect of the exogenous recombinant human VEGF 165 protein on clonogenic cell growth (data not shown), it is probable that endogenous VEGF regulates cell growth for the following reasons: human anti-VEGF, ie VEGFR2/Fc Chimera antibody, was able to inhibit clonogenic cell growth, and SU 1498, a
Figure 3
Effects of different agents on the colony formation of the OCI/AML-2 cell line. The cells were exposed to VEGFR2/Fc Chimera antibody of 500 ng/ml, SU 1498 of 10 m, LY 294002 of 50 m, Wortmannin of 10 m, L-NAME of 10 mm and SNP of 1 mm for 6 h (short, S) and 48 h (long, L) in suspension. After that, the cells were washed twice with PBS and cultured into mc as described in Materials and methods. The numbers of colonies are shown as percentages of control (no exposure). The results are mean ± s.d. of three independent experiments.
Leukemia powerful VEGFR2 (Flk-1/KDR) tyrosine kinase inhibitor, was even more effective in inhibiting colony formation (Figure 3) . XTT (cytotoxicity, measured three times, varied from 96 to 108% of control with these agents) and annexin V assays (Figure 4a) showed that the concentrations of the above-mentioned inhibitors were not toxic to AML cells in suspension. The flow cytometry method used here measures the intracytoplasmic part of the Flk-1/KDR receptor. Since anti-VEGF was effective, we may assume that the extracellular part of the Flk-1/KDR receptor of AML cells is functional.
Effect of SNP and L-NAME on AML clonogenic cell growth and cell survival
L-NAME of 10 mm caused a clear inhibition of colony formation in mc (Figure 3 ). This concentration did not cause any change in cell survival in cell suspension, as measured by either XTT (102% of control, n = 2) or annexin V assay (Figure 4b ). SNP of 1 mm was not cytotoxic for the cells either (data not shown). After a short exposure of 6 h it caused a clear stimulation of colony growth up to 185 ± 60% of control, which effect disappeared after longer exposure, actually inhibiting colony growth after 2 days of exposure ( Figure 3) .
Effect of PI3-K inhibitors on AML cell survival and clonogenic cell growth
In endothelial cells VEGF regulates eNOS through the PI3-K/Akt kinase pathway. Therefore, in this study, we used Wortmannin and LY294002 as PI3-K inhibitors. Wortmannin caused an obvious decrease in clonogenic cell growth of OCI/AML-2 cells (Figure 3) . It was also notable that Wortmannin caused some apoptosis of OCI/AML-2 cells at a concentration of 10 m, as shown in Figure 4b . LY 294002 is a more specific inhibitor of PI3-K than Wortmannin. It also caused, at a concentration of 50 m, distinct inhibition of the colony growth of OCI/AML-2 cells (Figure 3) . The viability of cells in suspension also decreased by 30% as analyzed by trypan blue.
Modulation of Akt kinase activity by the inhibitors of VEGF and PI3-K signaling pathways
Akt kinase activity of OCI/AML-2 cells was estimated by using Western blotting. OCI/AML-2 cells were exposed to inhibitors for 24 h. VEGFR2/Fc Chimera antibody caused a distinct decrease in the expression of phosphorylated, ie active Akt kinase as shown in Figure 5 . The same effect was also observed by SU 1498, a Flk-1/KDR tyrosine kinase inhibitor, and by LY 294002, a PI3-K inhibitor ( Figure 5 ).
Activity of NOS and its modulation
ENOS is a downstream target of active Akt kinase in endothelial cells. We analyzed whether the VEGF signaling pathway and NOS modulators affect the activity of NOS, ie the generation of NO by cells. Exposure time of the cells for modulators in these experiments was 2 days. We used radioactive method based on l-citrulline production from l-arginine by an active NOS and found that VEGFR2/Fc Chimera antibody decreased l-citrulline production to below 50% of control ( Figure 6 ). SU 1498, on the other hand, caused a decrease in activity to 65% of control ( Figure 6 ). Wortmannin caused an obvious decrease in NOS activity, and LY 294002 also caused distinct inhibition of NOS activity to 40% of control ( Figure 6 ). L-NAME, on the other hand, caused a decrease in activity below 60% of control ( Figure 6 ).
Figure 5
Detection of Akt kinase activity by Western blotting. OCI/AML-2 cells were exposed to VEGFR2/Fc Chimera antibody of 500 ng/ml, SU 1498 of 10 m, and LY294002 of 50 m for 24 h. After that, the cells were lysed in Laemmli buffer and loaded on to SDSpolyacrylamide gel and visualized by enhanced chemiluminescence and specific antibody. C, control (no exposure); 1, VEGFR2/Fc Chimera antibody; 2, SU 1498, 3, LY 294002. The experiment was repeated three times with comparable results.
Discussion
For the first time, we show here that eNOS modulates clonogenic blast cell growth in AML cells, and the cell growth is, at least partly, under the control of the VEGF signaling pathway.
Immunohistochemistry of randomly selected BM samples obtained from patients with AML showed that the expression of eNOS in blast cells was a common rather than exceptional event. On the other hand, blast cells did not express iNOS, and the expression of nNOS (data not shown) was negligible. This led us to the conclusion that eNOS is the most important NOS in AML blast cells. It was quite interesting to note in the present analysis of BM immunohistochemistry samples that eNOS expression concentrated in immature cells, while iNOS was observed in maturing granulocytic lineage cells either in AML or in the case of normal bone marrow. It is possible that the balance of eNOS and iNOS may affect the differentiation of hematopoietic cells. We did not, however, study this issue, but refer to previous publications, where at least active iNOS has been connected to the differentiation of neutrophils and monocytes. 23, 48 In AML, normal hematopoiesis is often decreased. It may be speculated that excessive NO produced by either AML cells or other cells may act as a suppressant of normal hematopoiesis, which role has been experimentally ascribed in vitro to
Figure 6
Activity of NOS after exposure of OCI/AML-2 cells to different agents. The cells were exposed to VEGFR2/Fc Chimera antibody of 500 ng/ml, SU 1498 of 10 m, Wortmannin of 10 m, LY294002 of 50 m, and L-NAME of 10 mm, after which the activity of NOS to produce NO was measured as a conversion of l-arginine to l-citrulline. The results are mean ± s.d. of three independent experiments. Leukemia exogenous NO. 18 At the same time, endogenous NO may maintain leukemia cell growth autocrinely or paracrinely, as observed in the present study. According to previous studies, however, the role of NO in leukemia cell growth has been shown to be notably controversial. NO donors are able to produce growth inhibition and even apoptosis of leukemia cells in a rate-and concentration-dependent manner. 21, 49 In the present study, furthermore, SNP, a generally known NO donor, either stimulated or inhibited colony formation of OCI/AML-2 cells, depending on exposure time. It is generally known that excessive NO may lead to disruption of hemeenzymes or formation of S-nitrosothiols or ONOO − radicals, leading to growth arrest or cell death. 50, 51 It is also known that NO may function as both an activator and an inhibitor of the cell death program, depending on the biological environment, ie the presence or absence of stimulatory or inhibitory cosignals. 50 If endogenous NO is an important stimulant for AML cell growth, the inhibitors of NOS might also have inhibitory effects on AML cells. L-NAME of 10 mm caused a distinct decrease in clonogenic cell proliferation in OCI/AML-2 cells. The concentration was not too toxic for cells, ie it did not produce cell death when measured by XTT and annexin V assays.
Previous studies have shown how important the presence of the Flk-1/KDR receptor is for the development of hematopoiesis. [30] [31] [32] Very primitive hematopoietic progenitor cells express Flk-1/KDR, 33 but as soon as the cells are committed to differentiate, this expression is lost. The randomly selected AML patients in the present study showed clear and uniform Flk-1/KDR expression in blast cells, while the expression of Flt-1, another VEGF receptor, was much less intensive. These results show some discrepancy with the studies by Fiedler and coworkers. 44 They showed by using the reverse transcriptase polymerase chain reaction (RT-PCR) method that the expression of Flt-1 is more common in AML than the expression of Flk-1/KDR. They studied 26 AML samples and found Flt-1 expression at mRNA level in 13/25 (52%) of samples while the expression of Flk-1/KDR at mRNA level was found in 5/26 (19%) of samples. In the present study, the expression of Flt-1 protein by immunohistochemistry was observed in 8/14 (57%) cases, which actually is comparable with the results of Fiedler and coworkers. In contrast, the expression of Flk-1/KDR in the present study was more common than in the above-mentioned study and was found by immunohistochemistry in 13/13 cases. This might be merely coincidence, since the patient material in both studies was quite small. In addition, the distribution of FAB groups was different in these studies reflecting perhaps different biological background of the disease. There are also other reports showing that AML cells express Flk-1/KDR, Flt-1 and Flt-4 receptors. [36] [37] [38] [39] Their significance for cell growth, however, has not been studied in detail. It is possible that leukemia cells may retain their less mature state at the molecular level by expressing Flk-1/KDR, which might have some benefit for their growth. We do not know whether Flk-1/KDR expression has any prognostic value in AML. However, all but one of the patients in the present study died of refractory disease. This issue should be studied in a larger patient series. There is already one report to show that high Flk-1/KDR expression correlates with poorer survival than low receptor expression in chronic lymphocytic leukemia. 52 We were interested in studying whether signaling through Flk-1/KDR takes place in AML. We used the OCI/AML-2 cell line, since we found it to express both Flk-1/KDR and VEGF by flow cytometry. RT-PCR of OCI/AML-2 cells indicated (data not shown) that VEGF mRNA was composed of four dif-ferent bands corresponding to proteins of 121, 165, 189 and 205 kDa. It is known that the 121 and 165 forms are diffusible proteins, which are secreted into the growth medium. We therefore used the ELISA kit for VEGF measurement, which also recognizes these two isoforms of VEGF. OCI/AML-2 cells produced VEGF. In a clonogenic cell culture assay, we did not find exogenous VEGF 165 to have any distinct effect on OCI/AML-2 cells. This might only mean that VEGF production in cells is so high that exogenous VEGF is not able to affect them. However, since the antibody that inhibits the VEGF effect through the Flk-1/KDR receptor also had some inhibitory effect on clonogenic cell growth, it is highly probable that endogenous VEGF influences the cells in an autocrine or paracrine way through Flk-1/KDR. The significance of the Flk-1/KDR receptor in maintaining OCI/AML-2 cell line growth was confirmed by using SU 1498, which inhibited the function of the receptor and also led to a decrease in cell growth. It should be noticed, however, that SU 1498 is not a specific inhibitor of Flk-1/KDR receptor, but is able to inhibit other tyrosine kinase receptors. In addition, we cannot totally rule out the significance of Flt-1 receptor in mediating the effect of VEGF in the OCI/AML-2 cell line, since SU1498 to some extent also inhibits this receptor. The expression of Flt-1, however, is not so evident as the expression of Flk-1/KDR in the OCI/AML-2 cell line clone we have used in our laboratory since 1992. There is also a report, that underlines the role of the Flk-1/KDR receptor in the transduction of VEGF signal in AML cells. 41 VEGF might, however, be an important growth factor for AML cells in another way. According to a previous study, VEGF produced by AML cells was able to activate endothelial cells to produce GM-CSF, which is known to be an important growth factor for AML cells. 44 It should be mentioned that there is already a study to show that VEGF produced by AML cells predicts the outcome of AML patients, underlining the significance of autocrine VEGF in AML. 38 The present study on a series of AML patients showed VEGF expression to be highly variable and not present in every case. Thus, the autocrine or paracrine loop does not necessarily operate in vivo. In spite of this, endocrine VEGF is easily available for blast cells from other cell sources in vivo, such as endothelial cells, even in the BM microenvironment.
There are various signal transduction pathways by which VEGF is able to activate eNOS in endothelial cells. These include the protein kinase C pathway 15, 16 and the mitogenactivated protein kinase pathway. 51 At present, however, the most important pathway activating eNOS in endothelial cells seems to be the pathway in which VEGF first activates its receptor Flk-1/KDR, leading to the activation of PI3-K and its downstream effector Akt kinase, which is known, on the other hand, to be a direct activator of eNOS. [12] [13] [14] We therefore concentrated here on investigating this pathway. We were able to show, using OCI/AML-2 cells, how the inactivation of Flk-1/KDR leads to a decrease in the activity of Akt kinase. Also, the PI3-K inhibitor LY294002 caused an obvious decrease in the Akt kinase activity of the cells. We hypothesized that if the inhibitors of Flk-1/KDR and PI3-K also cause a decrease in NOS activity, as NOS inhibitors do in these cells, a connection between these two signaling systems is probable. And this was really the case, the l-citrulline production of blast cells was decreased by the inhibitors of Flk-1/KDR and PI3-K. Furthermore, the use of these inhibitors also led to an inhibition of clonogenic cell growth, as did NOS inhibitors. It was interesting to note that PI3-K inhibitors induced apoptosis, while the inhibitors of Flk-1/KDR did not, although all inhibitors caused a distinct decrease in Akt kinase activity. It is known that eNOS is not the only downstream effector of Akt kinase. The other known effectors include GSK-3␤, transcription factors FKHR and NFB and molecules that regulate apoptosis, ie BAD and caspase-9. [53] [54] [55] [56] [57] The next interesting task will be to investigate the role of these factors in AML cell growth in the VEGF/NOS-mediated system. In previous studies the effect of NO on leukemia cell growth has been shown to be very variable. Exogenous NO seems to be more apoptotic to leukemic cells and especially to myeloid cells, while endogenously produced NO resist apoptosis, especially in lymphoid cells. 28 Our study shows that also in myeloid cells endogenous NO might have some role to resist apoptosis.
In conclusion, we observed that AML cells express eNOS. Its activation to produce NO may take place by autocrine or paracrine VEGF through Flk-1/KDR, PI3-K and Akt kinase. Modulation of this system affects clonogenic cell growth and cell survival and may open up new possibilities for AML therapy.
